Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmström MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM.
Kjeldsen JW, et al. Among authors: donia m.
Nat Med. 2022 Apr;28(4):871. doi: 10.1038/s41591-022-01771-w.
Nat Med. 2022.
PMID: 35260843
Free PMC article.
No abstract available.